ZIMVIE INC Stock Price, News & Analysis

ZimVie Inc. (Nasdaq: ZIMV), a leader in dental and spine markets, announced its participation in Morgan Stanley's 20th Annual Global Healthcare Conference in New York. Management, including President Vafa Jamali and CFO Rich Heppenstall, will present on September 13, 2022, at 7:20 AM EDT. The event will be accessible via a live and archived webcast. Established in March 2022 as a spin-off from Zimmer Biomet, ZimVie is dedicated to enhancing life sciences with innovative dental and spine solutions, serving over 70 countries worldwide.

ZimVie Inc. (ZIMV) reported Q2 2022 net sales of $233.4 million, down 11.5% from the prior year. The company experienced a net loss of ($8.7 million) with a net loss margin of (3.7%). Adjusted net income was $17.6 million and diluted EPS was (0.33), while adjusted diluted EPS was $0.67. Cash reserves rose to $130.1 million. The company revised its 2022 net sales guidance down to $915 - $930 million from $1.0 billion, citing foreign exchange headwinds. Adjusted EPS guidance was also lowered to $1.80 - $2.00.

ZimVie Inc. (Nasdaq: ZIMV), a leader in dental and spine markets, will report its financial results for Q2 2022 after market close on August 10, 2022. An audio webcast will follow at 4:30 p.m. ET, allowing investors to gain insights into the company’s performance post-spin-off from Zimmer Biomet. ZimVie focuses on a comprehensive product portfolio for spine and dental solutions, serving over 70 countries.

ZimVie Inc. announced a positive medical policy from Anthem Blue Cross Blue Shield regarding the use of its Tether™ device for treating pediatric scoliosis. Effective July 6, 2022, this decision expands treatment eligibility to over 30 million members. The Tether™ device is the first FDA-approved non-fusion treatment for scoliosis, backed by more than seven years of clinical data, with over 1,200 children treated since its introduction in 2019. This development is anticipated to enhance access to motion-preserving treatments for children and may encourage other insurers to follow suit.

ZimVie Inc. (Nasdaq: ZIMV) announced the launch of the FDA-cleared T3® PRO Tapered Implant and Encode® Emergence Healing Abutment on June 16, 2022. These products enhance dental restoration care with improved aesthetics and functionality. The T3 PRO builds on the existing T3 Implant line, demonstrating advanced design and high primary stability for immediate function. The Encode Emergence Abutment streamlines the impression process and promotes patient comfort. ZimVie aims to roll out these innovations in the U.S. and other regions as regulations permit.

ZimVie Inc. (Nasdaq: ZIMV) reported Q1 2022 net sales of $234.7 million, reflecting a 4.6% decrease year-over-year. Dental segment sales increased by 6.4% to $120.6 million, while spine sales fell by 13.9% to $114.1 million, attributed to market exits and product discontinuation. The company posted a net loss of $25.7 million or 10.9% of sales, with diluted EPS at ($0.98), but adjusted diluted EPS improved to $0.50. Adjusted EBITDA was $33.8 million, a decline from the previous year. ZimVie reaffirmed its 2022 guidance of $1.0 billion in net sales and adjusted EPS between $2.10 to $2.30.

ZimVie Inc. (Nasdaq: ZIMV), a leader in the dental and spine markets, will report its first-quarter 2022 financial results on May 5, 2022, after market close. A conference call with management is scheduled for 4:30 p.m. Eastern Time, allowing investors to engage by dialing in. ZimVie became an independent publicly traded entity in March 2022, having spun off from Zimmer Biomet, focusing on innovative dental and spine solutions. The company operates globally, supporting customers in over 70 countries.

ZimVie Inc. (Nasdaq: ZIMV) reported a third-party revenue of $1.009 billion for 2021, driven by $469 million in dental revenue and $540 million in spine revenue. The company experienced a 12.5% revenue increase compared to 2020, with dental revenue up 27.4% due to increased procedure volume post-COVID-19 restrictions. Despite an operating loss of $100.5 million, this was an improvement of 54.9% from 2020. The company reaffirmed its 2022 financial guidance, expecting revenue to remain flat at $1.0 billion and adjusted EPS between $2.10 and $2.30.

ZimVie Inc. began trading on the Nasdaq under the symbol ZIMV on March 1, 2022, marking its debut as an independent company following its separation from Zimmer Biomet. This strategic move aims to enhance the company's focus on its Dental and Spine product platforms, which together represent a $20 billion addressable market. ZimVie appointed a new Board of Directors with diverse healthcare experience to guide its growth and shareholder value.